Viral Vaccines
"Viral Vaccines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Suspensions of attenuated or killed viruses administered for the prevention or treatment of infectious viral disease.
Descriptor ID |
D014765
|
MeSH Number(s) |
D20.215.894.899
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Viral Vaccines".
Below are MeSH descriptors whose meaning is more specific than "Viral Vaccines".
This graph shows the total number of publications written about "Viral Vaccines" by people in this website by year, and whether "Viral Vaccines" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 3 | 1 | 4 | 1995 | 1 | 0 | 1 | 1996 | 1 | 2 | 3 | 1998 | 3 | 0 | 3 | 1999 | 0 | 2 | 2 | 2002 | 2 | 0 | 2 | 2003 | 1 | 0 | 1 | 2004 | 3 | 2 | 5 | 2005 | 2 | 3 | 5 | 2006 | 1 | 1 | 2 | 2007 | 1 | 0 | 1 | 2008 | 2 | 2 | 4 | 2009 | 2 | 0 | 2 | 2010 | 1 | 0 | 1 | 2011 | 0 | 1 | 1 | 2012 | 1 | 0 | 1 | 2013 | 1 | 0 | 1 | 2014 | 3 | 2 | 5 | 2015 | 1 | 1 | 2 | 2017 | 1 | 0 | 1 | 2018 | 4 | 0 | 4 | 2019 | 2 | 0 | 2 | 2020 | 3 | 1 | 4 | 2021 | 3 | 0 | 3 | 2022 | 2 | 0 | 2 | 2023 | 5 | 0 | 5 | 2024 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Viral Vaccines" by people in Profiles.
-
Yonts AB, Gaviria-Agudelo C, Kimberlin DW, O'Leary ST, Paulsen GC. Fall 2023 ACIP Update on Meningococcal, RSV, COVID-19, and Other Pediatric Vaccines. Pediatrics. 2024 Mar 01; 153(3).
-
Feldman AG, Beaty BL, Ferrolino JA, Maron G, Weidner HK, Ali SA, Bitterfeld L, Boulware MA, Campbell KM, Carr E, Chapman S, Chang YC, Cunningham R, Dallas RH, Dantuluri KL, Domenick BN, Ebel NH, Elisofon S, Fawaz R, Foca M, Gans HA, Gopalareddy VV, Gu C, Gupta NA, Harmann K, Hollenbeck J, Huppler AR, Jaramillo C, Kasi N, Kerkar N, Lerret S, Lobritto SJ, Lopez MJ, Marini E, Mavis A, Mehra S, Moats L, Mohandas S, Munoz FM, Mysore KR, Onsan C, Ovchinsky N, Perkins K, Postma S, Pratscher L, Rand EB, Rowe RK, Schultz D, Sear K, Sell ML, Sharma T, Stoll J, Vang M, Villarin D, Weaver C, Wood P, Woodford-Berry O, Yanni G, Danziger-Isakov LA. Safety and Immunogenicity of Live Viral Vaccines in a Multicenter Cohort of Pediatric Transplant Recipients. JAMA Netw Open. 2023 10 02; 6(10):e2337602.
-
Embi PJ, Levy ME, Patel P, DeSilva MB, Gaglani M, Dascomb K, Dunne MM, Klein NP, Ong TC, Grannis SJ, Natarajan K, Yang DH, Stenehjem E, Zerbo O, McEvoy C, Rao S, Thompson MG, Konatham D, Irving SA, Dixon BE, Han J, Schrader KE, Grisel N, Lewis N, Kharbanda AB, Barron MA, Reynolds S, Liao IC, Fadel WF, Rowley EA, Arndorfer J, Goddard K, Murthy K, Valvi NR, Weber ZA, Fireman B, Reese SE, Ball SW, Naleway AL. Effectiveness of COVID-19 vaccines at preventing emergency department or urgent care encounters and hospitalizations among immunocompromised adults: An observational study of real-world data across 10 US states from August-December 2021. Vaccine. 2023 08 23; 41(37):5424-5434.
-
Perkins-Oines S, Dias N, Krafsur G, Abdelsalam K, Perry G, Ensley D, Jones C, Chase CCL. The effect of neonatal vaccination for bovine respiratory disease in the face of a dual challenge with bovine viral diarrhea virus and Mannheimia hemolytica. Vaccine. 2023 05 05; 41(19):3080-3091.
-
Rando HM, Lordan R, Lee AJ, Naik A, Wellhausen N, Sell E, Kolla L, Gitter A, Greene CS. Application of Traditional Vaccine Development Strategies to SARS-CoV-2. mSystems. 2023 04 27; 8(2):e0092722.
-
Rando HM, Lordan R, Kolla L, Sell E, Lee AJ, Wellhausen N, Naik A, Kamil JP, Gitter A, Greene CS. The Coming of Age of Nucleic Acid Vaccines during COVID-19. mSystems. 2023 04 27; 8(2):e0092822.
-
Preston KB, Wong TAS, Lieberman MM, To A, Lai CY, Granados A, Thomasson H, Misamore J, Yalley-Ogunro J, Cabus M, Andersen H, Donini O, Lehrer AT, Randolph TW. Lyophilized Filovirus Glycoprotein Vaccines: Peroxides in a Vaccine Formulation with Polysorbate 80-Containing Adjuvant are Associated with Reduced Neutralizing Antibody Titers in Both Mice and Non-Human Primates. J Pharm Sci. 2022 12; 111(12):3424-3434.
-
Lucas CJ, Davenport BJ, Carpentier KS, Tinega AN, Morrison TE. Two Conserved Phenylalanine Residues in the E1 Fusion Loop of Alphaviruses Are Essential for Viral Infectivity. J Virol. 2022 05 11; 96(9):e0006422.
-
Preston KB, Wong TAS, To A, Tashiro TE, Lieberman MM, Granados A, Feliciano K, Harrison J, Yalley-Ogunro J, Elyard HA, Donini O, Lehrer AT, Randolph TW. Single-vial filovirus glycoprotein vaccines: Biophysical characteristics and immunogenicity after co-lyophilization with adjuvant. Vaccine. 2021 09 15; 39(39):5650-5657.
-
Powers JM, Haese NN, Denton M, Ando T, Kreklywich C, Bonin K, Streblow CE, Kreklywich N, Smith P, Broeckel R, DeFilippis V, Morrison TE, Heise MT, Streblow DN. Non-replicating adenovirus based Mayaro virus vaccine elicits protective immune responses and cross protects against other alphaviruses. PLoS Negl Trop Dis. 2021 04; 15(4):e0009308.
|
People People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|